Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan long-term extension study in geographic atrophy secondary to AMD
NL-OMON59257Phase 3Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Feb 2022
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegcetacoplan in age-related macular degeneration (AMD), sponsored by Apellis Pharmaceuticals. Primary endpoint: Incidence and severity of ocular and systemic adverse events. Started Feb 2022; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NL-OMON59257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59257.